Anika Therapeutics (NSDQ:ANIK) has inked an agreement with the Institute of Integrative Biology at the University of Liverpool to develop an injectable mesenchymal stem cell therapy to treat osteoarthritis.
As a result of the three-year research collaboration, the group hopes to have a lead candidate that it can take into clinical trials.
Get the full story at our sister site, Drug Delivery Business News.
The post Anika collabs to develop injectable stem cell therapy for osteoarthritis appeared first on MassDevice.